Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of intangible assets

Other operating expense (income), net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Quest Diagnostics

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quest Diagnostics reports robust 2022 performance amidst COVID-19 testing decline

Quest Diagnostics delivered strong financial performance in 2022, with revenue growth and strategic acquisitions driving expansion.
Challenges include the anticipated decline in COVID-19 testing revenues and regional healthcare recovery disparities post-pandemic.
Opportunities lie in advanced diagnostics investments, productivity enhancements, and upcoming investor day to showcase growth strategies.
Overall, Quest Diagnostics remains focused on long-term growth, margin improvement, and shareholder value creation.

Quest Diagnostics reports strong Q1 earnings, eyes growth opportunities

Quest Diagnostics' Q1 performance reflects robust revenue growth and strategic acquisitions positioning the company for future success. Challenges in margin progression and market expectations for MRD testing require attention, while opportunities in oncology distribution and consumer testing optimization offer avenues for growth.

Quest Diagnostics reports robust Q2 earnings, raises guidance amid challenges

Quest Diagnostics demonstrated strong financial performance in Q2 2023, with revenue growth, margin improvement, and raised guidance, despite challenges like high turnover and labor costs.
The company's strategic focus on innovation, acquisitions, and pricing strategies presents opportunities for sustained growth and market expansion in clinical areas like genomics and oncology.
Navigating challenges related to employee turnover and cost pressures while leveraging opportunities in M&A, value-based care, and technological advancements will be crucial for Quest Diagnostics' future success.

Quest Diagnostics reports robust Q3 earnings amidst COVID challenges

Quest Diagnostics delivered strong financial results in Q3, showcasing growth in base business and adjusted EPS. While facing challenges from COVID-19 testing revenue decline and regulatory uncertainties, the company remains focused on leveraging opportunities in growth investments and margin improvements.

Quest Diagnostics reports robust 2023 performance and optimistic 2024 outlook

Quest Diagnostics delivered strong financial performance in 2023, with revenue growth driven by acquisitions and strategic initiatives.
The company's focus on oncology, Alzheimer's offerings, and AI tools deployment positions them for continued growth and innovation.
While facing short-term challenges like regulatory uncertainties and pricing pressures, Quest Diagnostics remains confident in their long-term outlook and growth prospects.
With a positive guidance for 2024, including revenue and EPS expectations, the company aims to navigate headwinds and capitalize on opportunities for sustainable growth.

Quest Diagnostics reports robust Q1 results and strategic growth plans

Quest Diagnostics' Q1 performance showcased strong revenue growth and strategic investments in advanced diagnostics and automation.
While facing challenges like regulatory concerns and pricing pressures, the company's focus on acquisitions and operational efficiency drives growth.
Opportunities lie in continued automation efforts, market expansion in advanced diagnostics, and the positive outlook for key acquisitions.
Overall, Quest Diagnostics' solid financial results and raised guidance reflect a resilient business poised for future growth.

Quest Diagnostics reports robust Q2 earnings amid strategic acquisitions

Quest Diagnostics' Q2 2024 performance reflects solid revenue growth, operational efficiency, and strategic acquisitions driving expansion.
Despite challenges related to acquisition impact on EPS and industry dynamics, Quest's strong balance sheet and growth strategy position it well for the future.
The company's focus on advanced diagnostics, financial stability, and market opportunities underscores its resilience and growth potential in the healthcare sector.

Quest Diagnostics reports strong Q3 growth driven by acquisitions and advanced diagnostics

Quest Diagnostics' Q3 2024 performance reflects a robust growth trajectory driven by strategic acquisitions and a focus on advanced diagnostics.
While facing integration challenges and market uncertainties, the company's strong revenue streams and operational initiatives position it well for future growth.
With a reaffirmed long-term outlook and proactive acquisition strategy, Quest Diagnostics remains poised for continued success in the healthcare diagnostics sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SECAUCUS, N.J. and NUTLEY, N.J., Dec. 22, 2020 /PRNewswire/ -- Hackensack Meridian Health (HMH), the largest, most comprehensive and truly integrated health care network in New Jersey, and Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, are...

Hackensack Meridian Health and Quest Diagnostics Partner to Deliver High-Value, Innovative Laboratory Services

SECAUCUS, N.J., Dec. 17, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and The Commons Project, a non-profit public trust dedicated to building and operating global digital platforms and services for public good, today...

Quest Diagnostics and The Commons Project to Deliver Convenient Access to Lab Data -- Including COVID-19 Test Results -- Through the CommonHealth App

Shares of Quest Diagnostics Inc. rose 0.7% in premarket trading Wednesday, after the clinical lab testing company raised its full-year profit, revenue and cash flow outlook, as COVID-19 molecular testing volumes have been "significantly higher" than what was expected in late October. The company said it now expects 2020 adjusted earnings per share of "at least" $10.75, compared with its previous guidance range of $9.00 to $10.00 and the FactSet consensus of $10.01.

Quest Diagnostics stock rises after full-year profit and revenue outlook raised

SECAUCUS, N.J., Dec. 16, 2020 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today raised its financial outlook for full year 2020. Since the company reported its financial performance for the third quarter of...

Quest Diagnostics Raises Outlook for Full Year 2020

Conagra Brands

Leidos Hld

When screening the market in search of value opportunities, one method is to look for stocks whose trailing 12-month price-to-free-cash-flow ratios are low compared to that of the S&P 500 index, which stands at around 17.33 as of the writing of this article. In my opinion, these stocks are more likely to be selling at a compelling price.

A Trio of Opportunities Trading at Low Price-to-Free-Cash-Flow Ratios

SECAUCUS, N.J., Dec. 9, 2020 /PRNewswire/ -- A new Quest Diagnostics Health Trends™ study finds that three in four Americans who believed they needed a COVID-19 test (74%) chose not to get one, or delayed getting one, primarily due to concerns about exposure to the SARS-CoV-2 virus (30%)....

New Quest Diagnostics Health Trends™ Survey Reveals COVID-19 Testing Hesitancy Among Americans, With 3 of 4 Avoiding a Test When They Believed They Needed One

Abbott Labs

QuidelOrtho Corp

Labcorp Holdings Inc

Our indicative theme of Covid-19 Testing Stocks- which includes the stocks of companies that produce or carry out tests for the highly infectious virus - is up by about 51% year-to-date, on an equally weighted basis, compared to the broader S&P 500 which is up around 15%. While the conversation.

Quidel, Abbott, Quest: Why Covid-19 Testing Stocks Are Still Worth A Look

Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.

Is Quest Diagnostics (DGX) a Worthy Pick for Value Investors?

Quest Diagnostics (DGX) is moving ahead in terms of its growth strategy, which consists of five elements.

Quest Diagnostics (DGX) Grows on Two New Lab-Service Pacts

SECAUCUS, N.J., Nov. 24, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has achieved Gold status in the American Heart Association's 2020 Workplace Health Achievement Index, ranking the company's...

Quest Diagnostics Earns Gold Status in American Heart Association's 2020 Workplace Health Achievement Index

Quest Diagnostics has seen strong revenue and earnings bumps due to COVID-19 testing. While the pandemic won't last forever, I see management setting up the company for long-term success.

Quest Diagnostics: Not Just A COVID Play, Shares Are A Buy

Quest Diagnostics saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 93 the day before. The post Quest Diagnostics Stock Rating Improves Amid Surging Covid Testing Rates appeared first on Investor's Business Daily.

Quest Diagnostics Stock Rating Improves Amid Surging Covid Testing Rates

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

Quest Diagnostics (DGX) Down 1.2% Since Last Earnings Report: Can It Rebound?

Our indicative theme of Covid-19 Testing Stocks, which includes medical device and diagnostic companies that are involved in Covid-19 testing – is up by about 66% year-to-date, significantly outperforming the S&P 500 which has gained about 3% over the same period. Covid-19 testing stocks could be.

Quidel, Abbott, Quest: Testing Stocks To Watch As Covid-19 Cases Surge

Apple

Moderna

NIKE

Pfizer

PayPal

As we near the end of 2020, it's time to safeguard your portfolio before we enter the new year. Here are the top stocks to buy in November.

7 Top Stocks to Buy for November

SECAUCUS, N.J., Nov. 3, 2020 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Credit Suisse 29th Annual Virtual Healthcare Conference. Steve Rusckowski, Chairman,...

Quest Diagnostics To Speak At The Credit Suisse 29th Annual Virtual Healthcare Conference

Snap

Their numbers are set to keep rising during the pandemic.

2 Hot Coronavirus Stocks That Just Beat Earnings Expectations

Quest Diagnostics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating The post Stock Upgrades: Quest Diagnostics Among Companies Shows Rising Strength In Coronavirus Market appeared first on Investor's Business Daily.

Stock Upgrades: Quest Diagnostics Among Companies Shows Rising Strength In Coronavirus Market

Michaels

Meritage Homes

Pampa Energia

Winnebago

If you are not sure whether to invest your money in bonds or stocks, a key parameter that can show you the right direction is earnings yield.

5 High Earnings Yield Stocks That Make Attractive Bets

SECAUCUS, N.J., Oct. 27, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Catapult Health, the leading national provider of employer-sponsored Preventive Checkups, have formed a collaboration designed to help...

Quest Diagnostics and Catapult Health Provide Virtual Preventive Care Services for Employers During COVID-19 Pandemic and Beyond

In this article we will check out the progression of hedge fund sentiment towards Quest Diagnostics Incorporated (NYSE:DGX) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have access to expert networks and get tips from industry insiders. They also employ numerous Ivy League graduates and MBAs. Like everyone else, hedge funds perform miserably at times, but their consensus picks have historically outperformed the market after risk adjustments.

Were Hedge Funds Right About Crowding Into Quest Diagnostics (DGX)?

Quest Diagnostics (DGX) CEO, Stephen Rusckowski on Q3 2020 Results - Earnings Call Transcript

The company's business appears to be recovering nicely from the COVID-19 pandemic.

Here's Why Quest Diagnostics Made Investors Happy With Its Q3 Results

In Q3, Quest Diagnostics (DGX) sees strong signs of the health care system returning to pre-pandemic levels

Quest Diagnostics' (DGX) Q3 Earnings Beat, Base Volume Rises

Quest Diagnostics posted record quarterly growth for earnings and revenue, and hiked its outlook it had raised just last month. The post Quest Diagnostics Reports Record Quarterly Earnings, Sales Growth; Hikes Outlook appeared first on Investor's Business Daily.

News for Quest Diagnostics Stock (DGX)